{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"67.3","upperLimit":"87.1","value":"79.1"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"67"}],"units":"Participants"}],"description":"PFS is the time interval from start of treatment to documented evidence of disease progression. Progression is defined according to the Cheson response criteria. Disease progression as indicated by imaging scans at one year following therapy. Disease progression is defined as increase of 25% or more in the sum of the products of the longest perpendicular diameters of all measured lesions compared to the smallest previous measurements, or the appearance of any new lesion(s).","dispersionType":"95% Confidence Interval","groups":[{"description":"Combination chemo and biological therapy\n\nRituximab: 2 doses of rituximab every cycle: first dose on Day 1 and 2nd dose on Day 5\n\nFilgrastim: Filgrastim day 6 until absolute neutrophil count (ANC) reaches 5000 after the nadir, every cycle\n\nEtoposide, prednisone, vincristine, cyclophosphamide and doxorubicin hydrochloride (EPOCH): combination chemotherapy: EPOCH every 3 weeks for minimum of 3 cycles and max of 6 cycles","id":"OG000","title":"Arm 1-Combination Chemo and Biological Therapy"}],"paramType":"NUMBER","populationDescription":"One participant declined to participate before treatment started.","reportingStatus":"POSTED","timeFrame":"1 year","title":"Progression Free Survival at 1 Year","type":"PRIMARY","unitOfMeasure":"percentage of participants"}